Status:
UNKNOWN
Performance Evaluation of the Biological Diagnosis of HIT
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Heparin-induced Thrombocytopenia (HIT)
Eligibility:
All Genders
18+ years
Brief Summary
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular wei...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Adult patient (≥ 18 years of age)
- Hospitalized at HUS between 01/01/2009 and 31/12/2019
- Specimen sent to the HUS Hematology Laboratory for biological diagnosis of HIT between 01/01/2009 and 31/12/2019
- Data collected by the CRPV and analyzed by the HIT multidisciplinary group in order to reach a consensus decision on the presence or absence of HIT
- Patient does not object to the reuse of his medical data for scientific research purposes.
- Exclusion criteria:
- Patient for whom no test has been performed at the HUS Hematology Laboratory
- Patient for whom no data has been collected by the CRPV
- Patient for whom the HIT group could not confirm or deny the presence of HIT
Exclusion
Key Trial Info
Start Date :
June 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
894 Patients enrolled
Trial Details
Trial ID
NCT06180785
Start Date
June 27 2022
End Date
December 1 2023
Last Update
December 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratoire d'Hématologie - CHU de Strasbourg - France
Strasbourg, France, 67091